US Department of Defense – Neurofibromatosis Research Program (NFRP) – Clinical Trial Award
Sponsor: US Department of Defense
Closing Date: 26-Jul-2018
The Neurofibromatosis Research Program seeks to support innovative, high-impact research that will foster new directions for and address neglected issues in neurofibromatosis (NF) research; sponsor multidisciplinary and multi-institutional collaborations that will bring new perspectives to the field; promote translational and clinical studies to move promising ideas from bench to bedside; and develop a balanced portfolio of meritorious research related to all aspects of NF type 1 (NF1) and type 2 (NF2), and schwannomatosis. The FY18 NFRP strongly encourages research applications that specifically address the critical needs of the NF community in one or more of the Areas of Emphasis.

The NFRP Clinical Trial Award supports research with the potential to have a major impact on the treatment or management of NF. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept (i.e., pilot, first-in-human, or Phase 0) trials to demonstrate feasibility or inform the design of more advanced trials, through large-scale trials to determine efficacy in relevant patient populations.

• Investigators at or above the level of Assistant Professor (or equivalent) are eligible to apply.

Key Mechanism Elements
• Funds Phase 0, I, or II clinical trials relevant to NF and/or schwannomatosis. Combinations of phases are permitted.
Must support a clinical trial and may not be used for preclinical research studies.
• To encourage collaborations, NFRP will offer a Qualified Collaboration Option. Qualifying organizations include but are not limited to Federally funded partnerships/consortia with established infrastructure to support multi-institutional studies to leverage shared resources and core capabilities such as data management, clinical trial database administration, statistical analysis, tissue repositories, etc., that will improve study efficiency and reduce redundancies and duplication.

• Maximum funding of USD $800,000 for direct costs (plus indirect costs). Maximum funding of USD $1,000,000 for direct costs if requesting Qualified Collaborator Option (plus indirect costs).
• Maximum period of performance is 4 years.

Please see the U.S. Department of Defense Congressionally Directed Medical Research Program (CDMRP) website at and for further information. Pre-applications are submitted via the CDMRP’s Electronic Biomedical Research Application Portal (EBRAP) and full applications are submitted via For complete instructions for pre-applications and full applications, you must refer to both the Program Announcement and General Application Instructions documents.

Key Dates
Full applications due to UQR&I:
19 July 2018
Pre-applications (mandatory) close with US Department of Defense: 26 July 2018
Full applications close with US Department of Defense: 9 August 2018

Ahead of internal review, ensure all online components on EBRAP or are complete. To initiate review, email your completed Funding Application Coversheet to Interested applicants are strongly encouraged to make contact with the UQR&I international team (via well in advance of the UQR&I internal deadline to discuss their application.